Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis

a Multi-omics Cohort Study of Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis

This is a two stage nested case-control study to construct the hologram plane , explore biomarkers and screening original drugs of metastatic colorectal cancer.

Study Overview

• Status: Recruiting
• Conditions: Colorectal Cancer Stage III; Colorectal Cancer Stage IV

Detailed Description

Stage Ⅰ is a cross-sectional study to record selected information and biospecimen of more than 200 colorectal cancer cases( at least 160 stage Ⅲ cases,40 stage Ⅳ（synchronous metastasis）).Stage Ⅱ is a nested case-control study. 200 eligible cases enrolled in phaseⅠwill be followed up for 5 years to record recurrence, metastasis and to collect biospecimen . Each case with the study outcome will be matched with the corresponding control according to the proportion of 1:1 according to age, sex and other conditions, and further analysis will be made.

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

• Study Contact: Name: Sun Jing, PhD; Phone Number: 13524284622; Email: sj11788@rjh.com.cn

Study Locations

• China
  • Sahgnhai
    • Shanghai, Sahgnhai, China, 200000
      • Recruiting
      • Shanghai Ruijin Hospttal
      • Contact: Yanye Yang, Bachelor; Phone Number: +86-13636419858; Email: young0503@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The patients with CRC (Stage III and Stage IV)

Description

Inclusion Criteria:

• Baseline population (stage III colorectal cancer) inclusion criteria:

  1. Aged 18-75.
  2. Physical condition (ECOG) score ≤ 1.
  3. Colorectal adenocarcinoma was confirmed by histopathology.
  4. No family history of hereditary tumor.
  5. Accept standard radical resection of colorectal cancer, R0 resection, number of lymph node dissection ≥ 12.
  6. Preoperative clinical stage is stage III.
  7. Agree to receive standard fluorouracil ±oxaliplatin adjuvant chemotherapy for 3 to 6 months.
  8. Enough primary surgical or biopsy tissues for examination.
  9. Enough peripheral blood samples for examination.
  10. Agree to sign informed consent to participate in this project.

Baseline population (stage Ⅳ colorectal cancer) inclusion criteria:

1. Aged 18-75.
2. Histopathological diagnosed colonic or rectal adenocarcinoma of stage IV.
3. Not yet received antineoplastic therapy.
4. Baseline imaging evaluation shows at least one measurable focus.
5. Sufficient primary surgical or biopsy tissues and metastatic tissues of at least one organ for examination.
6. Enough peripheral blood samples for examination.
7. Expected survival time ≥ 3 months.
8. Provide information such as demography, current medical history or current tumor disease, pathological diagnosis and staging of tumor, physical status of ECOG, radiographic evaluation of tumor, etc.
9. Agree to sign informed consent to participate in this project.

Metastasis colorectal cancer cohort study inclusion criteria:

1. Aged 18-75.
2. Physical condition (ECOG) score ≤ 1.
3. Colorectal adenocarcinoma was confirmed by histopathology.
4. No family history of hereditary tumor.
5. Accept standard radical resection of colorectal cancer, R0 resection, number of lymph node dissection ≥ 12.
6. Preoperative clinical stage is stage III and the postoperative pathological stage was confirmed as stage III.
7. Agreed to receive standard fluorouracil ±oxaliplatin adjuvant chemotherapy for 3 to 6 months.
8. Enough primary surgical or biopsy tissues for examination.
9. Enough peripheral blood samples for examination.
10. Agree to sign informed consent to participate in this project.

Exclusion Criteria:

• Baseline population (stage III colorectal cancer) exclusion criteria:

  1. Participating in interventional clinical studies or receiving research treatments that influence patients' treatment decisions.
  2. Postoperative pathological stage was confirmed as stage II.
  3. Abnormal function of heart, lung, liver, kidney, hematopoiesis or bone marrow reserve, which cannot tolerate operation or chemotherapy.
  4. Diagnosed with malignant tumors that have progressed or need to be treated in the past 5 years, except for cured skin basal cells and skin squamous cell carcinoma.
  5. Having mental illness or other serious cardiovascular diseases.
  6. Pregnancy or lactation or planned pregnancy within one year.
  7. Emergency operation (perforation, bleeding, intestinal obstruction, etc.).

Baseline population (stage Ⅳcolorectal cancer) exclusion criteria:

1. Family history of hereditary colorectal cancer, such as Lynch syndrome, familial adenomatous polyposis, P-J syndrome, etc.
2. Nervous system metastasis.
3. Complicated with other malignant tumors.
4. Having poorly controlled chronic concomitant diseases that affect the prognosis.
5. Any complication that may affect the results of the study .

Metastasis colorectal cancer cohort study exclusion criteria:

1. Participating in interventional clinical studies or receiving research treatments that influence patients' treatment decisions.
2. Abnormal function of heart, lung, liver, kidney, hematopoiesis and bone marrow reserve, which cannot tolerate operation and chemotherapy.
3. Diagnoses with malignant tumors that have progressed or need to be treated in the past 5 years, except for cured skin basal cells and skin squamous cell carcinoma.
4. Having mental illness or other serious cardiovascular disease.
5. Pregnancy or lactation or planned pregnancy within one year.
6. Emergency operation (perforation, bleeding, intestinal obstruction, etc.).

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
recurrence or metastasis provened by imageologic diagnosis (PFS)	tumor metastasis or progression occurred during the enrolment period	May 31, 2023

Collaborators and Investigators

• Sponsor: Shanghai Minimally Invasive Surgery Center
• Collaborators: RenJi Hospital; Shanghai Jiao Tong University School of Medicine; Science and Technology Commission of Shanghai Municipality
• Investigators: Principal Investigator: Sun Jing, PhD, Shanghai Jiao Tong University School of Medicine

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2021
• Primary Completion (Anticipated): May 1, 2022
• Study Completion (Anticipated): May 1, 2023

Study Registration Dates

• First Submitted: January 12, 2021
• First Submitted That Met QC Criteria: January 15, 2021
• First Posted (Actual): January 19, 2021

Study Record Updates

• Last Update Posted (Actual): March 23, 2021
• Last Update Submitted That Met QC Criteria: March 19, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: Colorectal , Metastatisis ,Cancer Cell Fate Regulatory Mechanism
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Adenocarcinoma
• Other Study ID Numbers: Metastatic CRC cell fate

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No